Literature DB >> 20160489

Differences underlying EGFR and HER2 oncogene addiction.

Anthony C Faber, Kwok-Kin Wong, Jeffrey A Engelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20160489      PMCID： PMC2980856          DOI： 10.4161/cc.9.5.11096

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  9 in total

1.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors:  Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

2.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Authors:  Frederic Luciano; Arnaud Jacquel; Pascal Colosetti; Magali Herrant; Sebastien Cagnol; Gilles Pages; Patrick Auberger
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

3.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Authors:  Violeta Serra; Ben Markman; Maurizio Scaltriti; Pieter J A Eichhorn; Vanesa Valero; Marta Guzman; Maria Luisa Botero; Elisabeth Llonch; Francesco Atzori; Serena Di Cosimo; Michel Maira; Carlos Garcia-Echeverria; Josep Lluis Parra; Joaquin Arribas; José Baselga
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 4.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 5.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Jeffrey A Engelman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

6.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

7.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

Authors:  Anthony C Faber; Danan Li; Youngchul Song; Mei-Chih Liang; Beow Y Yeap; Roderick T Bronson; Eugene Lifshits; Zhao Chen; Sauveur-Michel Maira; Carlos García-Echeverría; Kwok-Kin Wong; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-22       Impact factor: 11.205

Review 8.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Authors:  Jeffrey A Engelman; Jeffrey Settleman
Journal:  Curr Opin Genet Dev       Date:  2008-03-05       Impact factor: 5.578

9.  Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

Authors:  Qing-Bai She; Sarat Chandarlapaty; Qing Ye; Jose Lobo; Kathleen M Haskell; Karen R Leander; Deborah DeFeo-Jones; Hans E Huber; Neal Rosen
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240
  9 in total
  20 in total

1.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

Authors:  Anthony C Faber; Ryan B Corcoran; Hiromichi Ebi; Lecia V Sequist; Belinda A Waltman; Euiheon Chung; Joao Incio; Subba R Digumarthy; Sarah F Pollack; Youngchul Song; Alona Muzikansky; Eugene Lifshits; Sylvie Roberge; Erik J Coffman; Cyril H Benes; Henry L Gómez; José Baselga; Carlos L Arteaga; Miguel N Rivera; Dora Dias-Santagata; Rakesh K Jain; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2011-07-22       Impact factor: 39.397

Review 2.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

3.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Authors:  Jaime Acquaviva; Hyun Jung Jun; Julie Lessard; Rolando Ruiz; Haihao Zhu; Melissa Donovan; Steve Woolfenden; Abraham Boskovitz; Ami Raval; Roderick T Bronson; Rolf Pfannl; Charles A Whittaker; David E Housman; Al Charest
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

Review 4.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Authors:  Aaron N Hata; Jeffrey A Engelman; Anthony C Faber
Journal:  Cancer Discov       Date:  2015-04-20       Impact factor: 39.397

Review 5.  Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

Authors:  Fabio Puglisi; Alessandro Marco Minisini; Carmine De Angelis; Grazia Arpino
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

6.  Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.

Authors:  Yongik Lee; Yian Wang; Michael James; Joseph H Jeong; Ming You
Journal:  Mol Carcinog       Date:  2015-06-04       Impact factor: 4.784

Review 7.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

Review 8.  Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.

Authors:  Joan T Garrett; Carlos L Arteaga
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

9.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

10.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Authors:  William H Chappell; Stephen L Abrams; Richard A Franklin; Michelle M LaHair; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Michele Milella; Agostino Tafuri; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.